复星医药(02196.HK)：复方聚乙二醇(3350)电解质散药品注册申请获受理

Core Viewpoint - Fosun Pharma's subsidiary Shanghai Chaohui Pharmaceutical has received acceptance for the drug registration application of Compound Polyethylene Glycol (3350) Electrolyte Powder by the National Medical Products Administration [1] Group 1: Drug Development - The Compound Polyethylene Glycol (3350) Electrolyte Powder is a chemical drug intended for the treatment of chronic constipation, excluding constipation caused by organic diseases [1] - As of October 2025, the group has invested approximately RMB 6.21 million (unaudited) in the research and development of the Compound Polyethylene Glycol Electrolyte Powder series, including this drug [1]